ARQT Arcutis Biotherapeutics, Inc.: institutional ownership and insider trading
301 funds reported holding $3.72B of Arcutis Biotherapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net sold $7.86M, with 39 new positions and 36 funds selling out; over the last 12 months insiders bought $0 and sold $16.3M on the open market.
Famous investors holding ARQT
- D. E. Shaw (D. E. Shaw & Co.): $104M, 0.1% of the portfolio
- Two Sigma (Two Sigma Investments): $17.4M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $14.8M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $33.3M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $1.53M, 0.0% of the portfolio
Largest institutional holders of ARQT
- SUVRETTA CAPITAL MANAGEMENT, LLC — $326M
- BlackRock, Inc. (BLK) — $277M
- Frazier Life Sciences Management, L.P. — $259M
- Rubric Capital Management LP — $217M
- VANGUARD GROUP INC — $211M
- Polar Capital Holdings Plc — $173M
- STATE STREET CORP (STT, STT-PG) — $153M
- VANGUARD CAPITAL MANAGEMENT LLC — $131M
- MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) — $117M
- JENNISON ASSOCIATES LLC — $111M
Recent ARQT insider trades
- Oct 15, 2026: Welgus Howard G. sold 4,728 shares ($127K)
- Sep 16, 2026: Matsuda Masaru sold 3,674 shares ($91.9K)
- Sep 15, 2026: Welgus Howard G. sold 4,730 shares ($114K)
- Sep 8, 2026: Matsuda Masaru sold 9,989 shares ($250K)
Members of Congress trading ARQT
- May 29, 2026: Gilbert Ray Cisneros, Jr. bought $1.00K–$15.0K
- Mar 3, 2026: Gilbert Ray Cisneros, Jr. bought $1.00K–$15.0K
- Dec 11, 2025: Gilbert Ray Cisneros, Jr. sold part of $1.00K–$15.0K
5%+ owners
- BlackRock, Inc.: 14.1% (Schedule 13G/A, filed Oct 5, 2026)
- Polar Capital Holdings Plc: 5.3% (Schedule 13G, filed Aug 14, 2026)